Tier 2 — strong

Comparative Efficacy and Pharmacokinetic Parameters of Micronized Creatine Monohydrate (KleanCREATINE™) in Active Men: A Randomized, Controlled Clinical Study

Pravin Aggarwal, Ramshyam Agarwal
Cureus 2026 18(2):e103091

Bibliography

PubMed
PMID 41809290
PubMed Central
PMC12968080
Funding
All trial-related expenses and investigational-product expenses were borne by Lasons India Pvt. Ltd.
Competing interests
Pravin Aggarwal reported employment with Lasons India Pvt. Ltd., which funded the trial and investigational product. The other author declared no conflict of interest.

Study snapshot

DesignTwo-phase randomized controlled clinical study: open-label crossover pharmacokinetics plus double-blind parallel efficacy phase
ModelHuman evidence synthesis or trial
Sample10 active men in the crossover pharmacokinetic phase; 52 active men in the eight-week parallel efficacy phase
Intervention3 g/day KleanCREATINE micronized creatine monohydrate versus a marketed creatine monohydrate
DurationSingle-dose pharmacokinetic phase plus 8-week efficacy phase
EndpointsPlasma creatine pharmacokinetics; Relative bioavailability; Strength; Muscle endurance; Body composition; Perceived exertion; Safety

What the study showed, in plain terms

2026 sponsor-funded study comparing a branded micronized monohydrate with another marketed monohydrate in active men.

Key findings

The study reported higher plasma exposure and faster peak concentration with the micronized product and several favorable training-related outcomes over eight weeks. The study did not measure intramuscular creatine and requires independent replication.

What this study can and cannot tell us

Small pharmacokinetic sample, modest eight-week efficacy sample, men only, sponsor funding and author employment, exploratory sample-size justification, and no direct measurement of muscle creatine stores.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified